Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$28.31
1.244.58%
À la fermeture: -
$28.25
-0.06-0.21%
Après les heures de négociation: 4:44 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Apellis Pharmaceuticals Inc a un objectif de cours consensus de $41.27, basé sur les évaluations des 23 analystes. Le plus élevé est de $106 attribué par Raymond James le janvier 11, 2024, et le plus bas est de $18 attribué par Goldman Sachs le septembre 26, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Wells Fargo, Goldman Sachs et Mizuho le octobre 15, 2025, septembre 26, 2025 et août 4, 2025. Avec un objectif de cours moyen de $24 entre Wells Fargo, Goldman Sachs et Mizuho, il y a une variation implicite de -15.04% downside pour Apellis Pharmaceuticals Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Wells Fargo
Goldman Sachs
Mizuho
JP Morgan
Citigroup
1calculé à partir des notes des analystes
Notes d'analystes pour Apellis Pharmaceuticals
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/15/2025 | 13.27% | Wells Fargo | $29 → $32 | Upgrade | Equal-Weight → Overweight | |||
09/26/2025 | -36.28% | Goldman Sachs | $26 → $18 | Downgrade | Neutral → Sell | |||
08/04/2025 | -22.12% | Mizuho | $21 → $22 | Maintains | Neutral | |||
08/04/2025 | 30.97% | JP Morgan | $35 → $37 | Maintains | Overweight | |||
08/01/2025 | 84.07% | Citigroup | $46 → $52 | Maintains | Buy | |||
08/01/2025 | -32.74% | RBC Capital | $17 → $19 | Maintains | Sector Perform | |||
08/01/2025 | 41.59% | Cantor Fitzgerald | $39 → $40 | Maintains | Overweight | |||
08/01/2025 | 76.99% | Raymond James | $52 → $50 | Maintains | Outperform | |||
07/29/2025 | -25.66% | Mizuho | $20 → $21 | Maintains | Neutral | |||
07/29/2025 | 62.83% | Citigroup | $41 → $46 | Maintains | Buy | |||
07/18/2025 | 76.99% | Baird | $47 → $50 | Maintains | Outperform | |||
07/16/2025 | -15.04% | B of A Securities | $23 → $24 | Maintains | Neutral | |||
07/02/2025 | -7.96% | Morgan Stanley | $25 → $26 | Maintains | Equal-Weight | |||
06/02/2025 | 2.65% | Wells Fargo | $26 → $29 | Maintains | Equal-Weight | |||
05/22/2025 | 45.13% | Citigroup | $49 → $41 | Maintains | Buy | |||
05/14/2025 | -29.2% | Mizuho | $30 → $20 | Maintains | Neutral | |||
05/09/2025 | 84.07% | Raymond James | $75 → $52 | Downgrade | Strong Buy → Outperform | |||
05/09/2025 | -18.58% | B of A Securities | $41 → $23 | Downgrade | Buy → Neutral | |||
05/08/2025 | -36.28% | RBC Capital | $21 → $18 | Maintains | Sector Perform | |||
05/08/2025 | -29.2% | Scotiabank | $28 → $20 | Maintains | Sector Perform | |||
05/08/2025 | -7.96% | Wells Fargo | $30 → $26 | Maintains | Equal-Weight | |||
05/08/2025 | 66.37% | Baird | $55 → $47 | Maintains | Outperform | |||
05/07/2025 | 2.65% | Needham | $40 → $29 | Maintains | Buy | |||
04/29/2025 | 55.75% | Cantor Fitzgerald | → $44 | Initiates | → Overweight | |||
04/21/2025 | -25.66% | RBC Capital | $24 → $21 | Maintains | Sector Perform | |||
04/02/2025 | 9.73% | Scotiabank | $30 → $31 | Maintains | Sector Perform | |||
03/04/2025 | 91.15% | JP Morgan | $50 → $54 | Maintains | Overweight | |||
03/03/2025 | -11.5% | RBC Capital | $26 → $25 | Maintains | Sector Perform | |||
03/03/2025 | 13.27% | Goldman Sachs | $36 → $32 | Maintains | Neutral | |||
03/03/2025 | 2.65% | Wedbush | $30 → $29 | Maintains | Neutral | |||
03/03/2025 | 101.77% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
02/13/2025 | 101.77% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
01/29/2025 | -7.96% | RBC Capital | $26 → $26 | Maintains | Sector Perform | |||
01/21/2025 | -7.96% | RBC Capital | $26 → $26 | Reiterates | Sector Perform → Sector Perform | |||
01/14/2025 | 101.77% | HC Wainwright & Co. | $57 → $57 | Reiterates | Buy → Buy | |||
12/17/2024 | 27.43% | Goldman Sachs | → $36 | Downgrade | Buy → Neutral | |||
11/21/2024 | 9.73% | Morgan Stanley | → $31 | Initiates | → Equal-Weight | |||
11/07/2024 | 94.69% | Baird | $92 → $55 | Maintains | Outperform | |||
11/06/2024 | 6.19% | Mizuho | $38 → $30 | Maintains | Neutral | |||
11/06/2024 | 80.53% | Citigroup | $63 → $51 | Maintains | Buy | |||
11/06/2024 | 27.43% | Goldman Sachs | $71 → $36 | Maintains | Buy | |||
11/06/2024 | -15.04% | RBC Capital | $25 → $24 | Maintains | Sector Perform | |||
11/06/2024 | 6.19% | Scotiabank | $35 → $30 | Maintains | Sector Perform | |||
11/06/2024 | 6.19% | Wells Fargo | $43 → $30 | Maintains | Equal-Weight | |||
11/06/2024 | 41.59% | Oppenheimer | $65 → $40 | Maintains | Outperform | |||
11/06/2024 | 13.27% | Piper Sandler | $40 → $32 | Maintains | Neutral | |||
11/06/2024 | 101.77% | HC Wainwright & Co. | $83 → $57 | Maintains | Buy | |||
11/06/2024 | 66.37% | B of A Securities | $61 → $47 | Maintains | Buy | |||
11/06/2024 | 112.39% | Needham | $85 → $60 | Maintains | Buy | |||
11/04/2024 | -11.5% | RBC Capital | $25 → $25 | Reiterates | Sector Perform → Sector Perform | |||
10/24/2024 | 34.51% | Mizuho | $39 → $38 | Maintains | Neutral | |||
10/16/2024 | 23.89% | Scotiabank | → $35 | Initiates | → Sector Perform | |||
10/16/2024 | — | William Blair | — | Initiates | → Outperform | |||
09/24/2024 | 52.21% | Wells Fargo | $47 → $43 | Maintains | Equal-Weight | |||
09/23/2024 | 225.66% | Baird | $96 → $92 | Maintains | Outperform | |||
09/20/2024 | 38.05% | Mizuho | $42 → $39 | Maintains | Neutral | |||
09/20/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
09/13/2024 | 101.77% | JP Morgan | $64 → $57 | Maintains | Overweight | |||
08/13/2024 | 126.55% | JP Morgan | $72 → $64 | Maintains | Overweight | |||
08/09/2024 | 193.81% | UBS | $85 → $83 | Maintains | Buy | |||
08/09/2024 | 45.13% | Wedbush | $38 → $41 | Maintains | Neutral | |||
08/09/2024 | 161.95% | Goldman Sachs | $66 → $74 | Maintains | Buy | |||
08/09/2024 | 239.82% | Baird | $86 → $96 | Maintains | Outperform | |||
08/09/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
08/02/2024 | 193.81% | HC Wainwright & Co. | $92 → $83 | Maintains | Buy | |||
08/02/2024 | 133.63% | Goldman Sachs | $77 → $66 | Maintains | Buy | |||
08/02/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
07/31/2024 | 183.19% | Jefferies | $80 → $80 | Maintains | Buy | |||
07/26/2024 | 204.42% | Baird | $100 → $86 | Maintains | Outperform | |||
07/23/2024 | 253.98% | Baird | $100 → $100 | Maintains | Outperform | |||
07/17/2024 | 172.57% | Goldman Sachs | $90 → $77 | Maintains | Buy | |||
06/28/2024 | 253.98% | Baird | $100 → $100 | Maintains | Outperform | |||
05/31/2024 | 62.83% | Piper Sandler | → $46 | Initiates | → Neutral | |||
05/28/2024 | 225.66% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
05/23/2024 | 69.91% | Wells Fargo | $57 → $48 | Maintains | Equal-Weight | |||
05/08/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
05/08/2024 | 112.39% | Citigroup | $67 → $60 | Maintains | Buy | |||
05/08/2024 | 225.66% | HC Wainwright & Co. | → $92 | Reiterates | Buy → Buy | |||
05/08/2024 | 200.88% | UBS | $89 → $85 | Maintains | Buy | |||
04/29/2024 | 84.07% | Mizuho | $60 → $52 | Maintains | Neutral | |||
04/26/2024 | 225.66% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
04/25/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
04/17/2024 | 101.77% | Wedbush | $67 → $57 | Maintains | Neutral | |||
04/15/2024 | 225.66% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
04/09/2024 | 200.88% | Needham | $85 → $85 | Reiterates | Buy → Buy | |||
03/27/2024 | 112.39% | Mizuho | $60 → $60 | Maintains | Neutral | |||
03/06/2024 | 179.65% | JP Morgan | $78 → $79 | Maintains | Overweight | |||
03/04/2024 | 215.04% | UBS | $87 → $89 | Maintains | Buy | |||
02/28/2024 | 225.66% | HC Wainwright & Co. | $92 → $92 | Reiterates | Buy → Buy | |||
02/28/2024 | 137.17% | Wedbush | $60 → $67 | Maintains | Neutral | |||
02/16/2024 | 112.39% | Mizuho | $49 → $60 | Maintains | Neutral | |||
02/06/2024 | 186.73% | Baird | → $81 | Reiterates | Outperform → Outperform | |||
02/05/2024 | 183.19% | Jefferies | $68 → $80 | Upgrade | Hold → Buy | |||
01/30/2024 | 179.65% | Oppenheimer | $75 → $79 | Maintains | Outperform | |||
01/24/2024 | 165.49% | Needham | $70 → $75 | Maintains | Buy | |||
01/17/2024 | 186.73% | Baird | $71 → $81 | Maintains | Outperform | |||
01/17/2024 | 225.66% | HC Wainwright & Co. | $82 → $92 | Maintains | Buy | |||
01/12/2024 | 112.39% | Wedbush | $39 → $60 | Maintains | Neutral | |||
01/11/2024 | 275.22% | Raymond James | $67 → $106 | Maintains | Strong Buy | |||
01/09/2024 | 218.58% | Goldman Sachs | $65 → $90 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action Apellis Pharmaceuticals (APLS) ?
Le dernier objectif de prix pour Apellis Pharmaceuticals (NASDAQ:APLS) a été rapporté par Wells Fargo le octobre 15, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $32.00 s'attendant à ce que APLS se rise dans les 12 prochains mois (un possible changement de 13.27% upside). 51 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Apellis Pharmaceuticals (APLS) ?
La dernière note d'analyste pour Apellis Pharmaceuticals (NASDAQ:APLS) a été fournie par Wells Fargo, et Apellis Pharmaceuticals amélioré leur note overweight.
Quand a eu lieu la dernière mise à niveau pour Apellis Pharmaceuticals (APLS) ?
La dernière amélioration pour Apellis Pharmaceuticals Inc a eu lieu le octobre 15, 2025 lorsque Wells Fargo a augmenté leur objectif de prix à $32. Wells Fargo avait précédemment an equal-weight pour Apellis Pharmaceuticals Inc.
Quand a eu lieu la dernière dégradation pour Apellis Pharmaceuticals (APLS) ?
La dernière réduction pour Apellis Pharmaceuticals Inc a eu lieu le septembre 26, 2025 lorsque Goldman Sachs a changé leur objectif de prix de $26 à $18 pour Apellis Pharmaceuticals Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Apellis Pharmaceuticals (APLS) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Apellis Pharmaceuticals, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Apellis Pharmaceuticals a été déposée le octobre 15, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 15, 2026.
La note d'analyste pour Apellis Pharmaceuticals (APLS) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Apellis Pharmaceuticals (APLS) était un amélioré avec un objectif de prix de $29.00 à $32.00. Le prix actuel de Apellis Pharmaceuticals (APLS) est de $28.25, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.